It's been speculated the moderately larger efficacy of AMP-based mostly brokers compared with MPH-based mostly agents in ADHD might be associated with differences within their molecular steps (33), but to date there is not any conclusive clinical evidence to assist this speculation. Also, there is not any conclusive clinical proof supporting a pote

fThe certainty ofwel the evidence was downgraded by one level owing to moderate statistical heterogeneity.dextro?amphetamine ? dextroamphetamine ? lisdexamphetamin ? dextroamfetamine ? lisdexamfetamin ? amphetamine a d ? d amphetamine ? d?amphetamine ? dexamfetamine ? dextro amphetamine ?The net result of this activity kan zijn increased efflux ofw